GlaxoSmithkline Pharmaceuticals Limited (GLAXO.BO)
| Previous close | 2,103.55 |
| Open | 2,105.00 |
| Bid | 2,086.90 x 0 |
| Ask | 2,095.50 x 0 |
| Day's range | 2,078.40 - 2,144.55 |
| 52-week range | 1,242.00 - 2,649.95 |
| Volume | |
| Avg. volume | 9,816 |
| Market cap | 354.711B |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 67.26 |
| EPS (TTM) | 31.13 |
| Earnings date | 17 May 2024 |
| Forward dividend & yield | 32.00 (1.52%) |
| Ex-dividend date | 30 Jun 2023 |
| 1y target est | 1,238.59 |
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
ZacksGSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
